A detailed history of Woodline Partners LP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 1,027,494 shares of TSHA stock, worth $2.33 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,027,494
Previous 1,026,269 0.12%
Holding current value
$2.33 Million
Previous $2.3 Million 10.14%
% of portfolio
0.02%
Previous 0.02%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.01 - $2.46 $2,462 - $3,013
1,225 Added 0.12%
1,027,494 $2.07 Million
Q2 2024

Aug 14, 2024

BUY
$2.04 - $4.17 $2.09 Million - $4.28 Million
1,026,269 New
1,026,269 $2.3 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $110M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.